Header Logo

Connection

CHARLES WYKOFF to Humans

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Humans.
CHARLES WYKOFF
Connection Strength
2.181
Humans
  1. Morphologic Stages of Full-Thickness Macular Hole on Spectral-Domain OCT. Ophthalmol Retina. 2025 Apr; 9(4):305-313.
    View in: PubMed
    Score: 0.026
  2. CLINICALLY RELEVANT POSTERIOR VITREOUS DETACHMENT STAGING USING CIRCUMPAPILLARY AND MACULAR VOLUME OPTICAL COHERENCE TOMOGRAPHY. Retina. 2024 08 01; 44(8):1441-1448.
    View in: PubMed
    Score: 0.026
  3. Syfovre Approval for Geographic Atrophy. JAMA Ophthalmol. 2024 Jul 01; 142(7):685-686.
    View in: PubMed
    Score: 0.025
  4. SUPRACHOROIDAL SPACE INJECTION TECHNIQUE: Expert Panel Guidance. Retina. 2024 06 01; 44(6):939-949.
    View in: PubMed
    Score: 0.025
  5. Retinal non-perfusion: recognizing and defining what is important. Eye (Lond). 2024 Jun; 38(9):1608-1609.
    View in: PubMed
    Score: 0.025
  6. Free-Floating Pigmented Vitreous Cysts: Clinical-Histopathologic Correlation. Ophthalmic Surg Lasers Imaging Retina. 2024 Jan; 55(1):55-58.
    View in: PubMed
    Score: 0.025
  7. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun; 131(6):708-723.
    View in: PubMed
    Score: 0.025
  8. Treatment of geographic atrophy: an update on data related to pegcetacoplan. Curr Opin Ophthalmol. 2024 Jan 01; 35(1):64-72.
    View in: PubMed
    Score: 0.024
  9. Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmol Retina. 2024 Mar; 8(3):223-233.
    View in: PubMed
    Score: 0.024
  10. Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise. Ophthalmic Surg Lasers Imaging Retina. 2023 10; 54(10):589-598.
    View in: PubMed
    Score: 0.024
  11. Clinically Labeled Contrastive Learning for OCT Biomarker Classification. IEEE J Biomed Health Inform. 2023 09; 27(9):4397-4408.
    View in: PubMed
    Score: 0.024
  12. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023 09 01; 141(9):834-842.
    View in: PubMed
    Score: 0.024
  13. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024 04; 260:70-83.
    View in: PubMed
    Score: 0.024
  14. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmol. 2022 12; 7(1).
    View in: PubMed
    Score: 0.023
  15. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials. Eye (Lond). 2023 07; 37(10):1966-1974.
    View in: PubMed
    Score: 0.023
  16. Favorable Anti-VEGF Crunch Syndrome: Nonsurgical Relief of Vitreoretinal Traction in Eyes With Proliferative Diabetic Retinopathy and Tractional Retinal Detachment. Ophthalmic Surg Lasers Imaging Retina. 2022 08; 53(8):455-459.
    View in: PubMed
    Score: 0.022
  17. Frequency and timing of antivascular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context. BMJ Open Ophthalmol. 2022 08; 7(1).
    View in: PubMed
    Score: 0.022
  18. Role of Positioning after Full-Thickness Macular Hole Surgery: A Systematic Review and Meta-Analysis. Ophthalmol Retina. 2023 01; 7(1):33-43.
    View in: PubMed
    Score: 0.022
  19. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2022 07; 6(7):557-566.
    View in: PubMed
    Score: 0.022
  20. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 02 19; 399(10326):741-755.
    View in: PubMed
    Score: 0.021
  21. Retinal non-perfusion in diabetic retinopathy. Eye (Lond). 2022 02; 36(2):249-256.
    View in: PubMed
    Score: 0.021
  22. Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis. Can J Ophthalmol. 2023 06; 58(3):252-261.
    View in: PubMed
    Score: 0.021
  23. Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 03; 235:131-142.
    View in: PubMed
    Score: 0.021
  24. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2021 Jun; 27(6):743-752.
    View in: PubMed
    Score: 0.021
  25. Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration. BioDrugs. 2021 May; 35(3):303-323.
    View in: PubMed
    Score: 0.020
  26. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021 09; 128(9):1325-1336.
    View in: PubMed
    Score: 0.020
  27. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes. Am J Ophthalmol. 2021 06; 226:126-136.
    View in: PubMed
    Score: 0.020
  28. Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy. Diabetes Care. 2021 03; 44(3):748-756.
    View in: PubMed
    Score: 0.020
  29. Reply. Ophthalmol Retina. 2021 01; 5(1):e1-e2.
    View in: PubMed
    Score: 0.020
  30. Home Monitoring of Age-Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization. Ophthalmol Retina. 2021 04; 5(4):348-356.
    View in: PubMed
    Score: 0.019
  31. Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. Ophthalmol Retina. 2021 03; 5(3):224-233.
    View in: PubMed
    Score: 0.019
  32. Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice. Am J Ophthalmol. 2020 07; 215:66-71.
    View in: PubMed
    Score: 0.019
  33. Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. Am J Ophthalmol. 2020 02; 210:86-96.
    View in: PubMed
    Score: 0.018
  34. Protecting Vision in Patients With Diabetes With Ultra-Widefield Imaging: A Review of Current Literature. Ophthalmic Surg Lasers Imaging Retina. 2019 10 01; 50(10):639-648.
    View in: PubMed
    Score: 0.018
  35. Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes. Ophthalmic Surg Lasers Imaging Retina. 2019 09 01; 50(9):e250-e256.
    View in: PubMed
    Score: 0.018
  36. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. Ophthalmol Retina. 2019 12; 3(12):1076-1086.
    View in: PubMed
    Score: 0.018
  37. Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results. Ophthalmol Retina. 2019 11; 3(11):917-919.
    View in: PubMed
    Score: 0.018
  38. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA?Study. Ophthalmology. 2019 08; 126(8):1171-1180.
    View in: PubMed
    Score: 0.018
  39. Re: Adrean et?al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053). Ophthalmology. 2019 03; 126(3):e18-e19.
    View in: PubMed
    Score: 0.018
  40. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019 Aug; 97(5):460-472.
    View in: PubMed
    Score: 0.017
  41. Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes. Graefes Arch Clin Exp Ophthalmol. 2019 May; 257(5):883-889.
    View in: PubMed
    Score: 0.017
  42. Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System. Ophthalmic Surg Lasers Imaging Retina. 2018 12 01; 49(12):913-917.
    View in: PubMed
    Score: 0.017
  43. Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2018 09 01; 49(9):692-697.
    View in: PubMed
    Score: 0.017
  44. Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial. Ophthalmic Surg Lasers Imaging Retina. 2018 04 01; 49(4):258-264.
    View in: PubMed
    Score: 0.017
  45. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. J Manag Care Spec Pharm. 2018 Feb; 24(2-a Suppl):S3-S15.
    View in: PubMed
    Score: 0.016
  46. Diagnostic and Therapeutic Challenges. Retina. 2018 Jan; 38(1):203-206.
    View in: PubMed
    Score: 0.016
  47. The Intersection of Diabetes Mellitus and Cataract Surgery: Current State of Management. Ophthalmol Retina. 2018 02; 2(2):83-85.
    View in: PubMed
    Score: 0.016
  48. Intravitreal aflibercept for proliferative diabetic retinopathy. Lancet. 2017 11 11; 390(10108):2141.
    View in: PubMed
    Score: 0.016
  49. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br J Ophthalmol. 2018 05; 102(5):631-636.
    View in: PubMed
    Score: 0.016
  50. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018 04; 102(4):460-464.
    View in: PubMed
    Score: 0.016
  51. THE ASSOCIATION OF EPIRETINAL MEMBRANE WITH MACULAR HOLE FORMATION AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR. Retina. 2017 Jun; 37(6):1073-1078.
    View in: PubMed
    Score: 0.016
  52. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol. 2017 Aug; 180:8-17.
    View in: PubMed
    Score: 0.016
  53. Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy. Curr Opin Ophthalmol. 2017 May; 28(3):213-218.
    View in: PubMed
    Score: 0.015
  54. Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. Ophthalmology. 2017 06; 124(6):919-921.
    View in: PubMed
    Score: 0.015
  55. Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis: Clinical Characteristics of 36 Eyes. Ophthalmology. 2017 05; 124(5):583-595.
    View in: PubMed
    Score: 0.015
  56. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Ophthalmology. 2017 04; 124(4):440-449.
    View in: PubMed
    Score: 0.015
  57. Diagnostic and Therapeutic Challenges. Retina. 2016 Nov; 36(11):2239-2245.
    View in: PubMed
    Score: 0.015
  58. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. Am J Ophthalmol. 2017 Jan; 173:56-63.
    View in: PubMed
    Score: 0.015
  59. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics. Retina. 2016 Jul; 36(7):1349-56.
    View in: PubMed
    Score: 0.015
  60. Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. Ophthalmology. 2016 08; 123(8):1716-1721.
    View in: PubMed
    Score: 0.014
  61. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2016 Apr 01; 47(4):308-12.
    View in: PubMed
    Score: 0.014
  62. CHOROIDAL NEOVASCULARIZATION SECONDARY TO ALEXANDRITE LASER EXPOSURE. Retin Cases Brief Rep. 2016; 10(3):244-8.
    View in: PubMed
    Score: 0.014
  63. GRANULAR HYPERREFLECTIVE SPECKS BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS SIGNS OF WEST NILE VIRUS INFECTION: THE STARDUST SIGN. Retin Cases Brief Rep. 2016; 10(4):349-53.
    View in: PubMed
    Score: 0.014
  64. Reply: To PMID 24914476. Retina. 2015 Oct; 35(10):e61-3.
    View in: PubMed
    Score: 0.014
  65. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015 Dec; 122(12):2514-22.
    View in: PubMed
    Score: 0.014
  66. Primary rhegmatogenous retinal detachment repair: evidence supports an individualised approach. Br J Ophthalmol. 2015 Nov; 99(11):1451-3.
    View in: PubMed
    Score: 0.014
  67. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar; 46(3):302-5.
    View in: PubMed
    Score: 0.013
  68. Progressive retinal nonperfusion in ischemic central retinal vein occlusion. Retina. 2015 Jan; 35(1):43-7.
    View in: PubMed
    Score: 0.013
  69. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul; 98(7):951-5.
    View in: PubMed
    Score: 0.012
  70. What is the optimal timing for rhegmatogenous retinal detachment repair? JAMA Ophthalmol. 2013 Nov; 131(11):1399-400.
    View in: PubMed
    Score: 0.012
  71. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology. 2013 Sep; 120(9):1945-6.e1.
    View in: PubMed
    Score: 0.012
  72. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr; 44(2):121-6.
    View in: PubMed
    Score: 0.012
  73. Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics. Am J Ophthalmol. 2011 Nov; 152(5):717-9.e2.
    View in: PubMed
    Score: 0.011
  74. Preoperative evaluation for patients with choroidal/ciliary body melanomas: what is necessary? Am J Ophthalmol. 2011 Jun; 151(6):921-4.
    View in: PubMed
    Score: 0.010
  75. Endophthalmitis after intravitreal injection: prevention and management. Retina. 2011 Apr; 31(4):633-5.
    View in: PubMed
    Score: 0.010
  76. Anti-vascular endothelial growth factor agents for pediatric retinal diseases. Int Ophthalmol Clin. 2011; 51(1):185-99.
    View in: PubMed
    Score: 0.010
  77. Allergy to povidone-iodine and cephalosporins: the clinical dilemma in ophthalmic use. Am J Ophthalmol. 2011 Jan; 151(1):4-6.
    View in: PubMed
    Score: 0.010
  78. Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital (2002-2009). Am J Ophthalmol. 2010 Sep; 150(3):392-398.e2.
    View in: PubMed
    Score: 0.010
  79. Fovea-sparing retinal detachments: time to surgery and visual outcomes. Am J Ophthalmol. 2010 Aug; 150(2):205-210.e2.
    View in: PubMed
    Score: 0.010
  80. Intraoperative OCT of a full-thickness macular hole before and after internal limiting membrane peeling. Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb; 41(1):7-11.
    View in: PubMed
    Score: 0.009
  81. Intraocular cryptococcoma. Arch Ophthalmol. 2009 May; 127(5):700-2.
    View in: PubMed
    Score: 0.009
  82. Atypical teratoid/rhabdoid tumor arising from the third cranial nerve. J Neuroophthalmol. 2008 Sep; 28(3):207-11.
    View in: PubMed
    Score: 0.008
  83. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology. 2008 Sep; 115(9):1501-7, 1507.e1-2.
    View in: PubMed
    Score: 0.008
  84. Myopic laser in situ keratomileusis in eyes with thick corneas. J Cataract Refract Surg. 2006 May; 32(5):900-1.
    View in: PubMed
    Score: 0.007
  85. Progressive inner retinal neurodegeneration in non-proliferative macular telangiectasia type 2. Br J Ophthalmol. 2025 Feb 24; 109(3):401-407.
    View in: PubMed
    Score: 0.007
  86. Accurate prediction of disease-risk factors from volumetric medical scans by a deep vision model pre-trained with 2D scans. Nat Biomed Eng. 2025 Apr; 9(4):507-520.
    View in: PubMed
    Score: 0.006
  87. Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage. Surv Ophthalmol. 2025 Jan-Feb; 70(1):96-105.
    View in: PubMed
    Score: 0.006
  88. MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2025 Feb; 132(2):131-140.
    View in: PubMed
    Score: 0.006
  89. Risk factors for development of hyper-reflective foci overlying drusen in eyes with intermediate age-related macular degeneration. Br J Ophthalmol. 2024 Aug 22; 108(9):1234-1239.
    View in: PubMed
    Score: 0.006
  90. Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy. Can J Ophthalmol. 2025 Apr; 60(2):91-99.
    View in: PubMed
    Score: 0.006
  91. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
    View in: PubMed
    Score: 0.006
  92. Exploring the fragility of meta-analyses in ophthalmology: a systematic review. Eye (Lond). 2024 Nov; 38(16):3153-3160.
    View in: PubMed
    Score: 0.006
  93. Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. Can J Ophthalmol. 2025 Feb; 60(1):e92-e99.
    View in: PubMed
    Score: 0.006
  94. MANAGEMENT OF LARGE FULL-THICKNESS MACULAR HOLES: Long-Term Outcomes of Internal Limiting Membrane Flaps and Internal Limiting Membrane Peels. Retina. 2024 07 01; 44(7):1165-1170.
    View in: PubMed
    Score: 0.006
  95. Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration: A Cross Sectional Study. Ophthalmol Retina. 2024 Sep; 8(9):854-862.
    View in: PubMed
    Score: 0.006
  96. Predictive Factors Influencing the Evolution of Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration Eyes. Ophthalmol Retina. 2024 Sep; 8(9):863-871.
    View in: PubMed
    Score: 0.006
  97. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet. 2024 04 20; 403(10436):1563-1573.
    View in: PubMed
    Score: 0.006
  98. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer. 2004 Mar 22; 90(6):1235-43.
    View in: PubMed
    Score: 0.006
  99. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 03 23; 403(10432):1153-1163.
    View in: PubMed
    Score: 0.006
  100. The ophthalmologist's guide to evaluating the certainty of evidence using the GRADE approach. Eye (Lond). 2024 Jun; 38(9):1601-1604.
    View in: PubMed
    Score: 0.006
  101. Topographic analysis of local OCT biomarkers which predict progression to atrophy in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024 Jul; 262(7):2083-2091.
    View in: PubMed
    Score: 0.006
  102. Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial. Ocul Immunol Inflamm. 2024 Oct; 32(8):1556-1563.
    View in: PubMed
    Score: 0.006
  103. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 12 01; 141(12):1152-1160.
    View in: PubMed
    Score: 0.006
  104. The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis. Surv Ophthalmol. 2024 May-Jun; 69(3):349-361.
    View in: PubMed
    Score: 0.006
  105. Evaluation of postoperative ophthalmology patient instructions from ChatGPT and Google Search. Can J Ophthalmol. 2024 Feb; 59(1):e69-e71.
    View in: PubMed
    Score: 0.006
  106. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023 10 21; 402(10411):1434-1448.
    View in: PubMed
    Score: 0.006
  107. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
    View in: PubMed
    Score: 0.006
  108. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 10 21; 402(10411):1449-1458.
    View in: PubMed
    Score: 0.006
  109. Surgical Management of Full-Thickness Macular Holes in Macular Telangiectasia Type 2: A Global Multicenter Study. Ophthalmology. 2024 Jan; 131(1):66-77.
    View in: PubMed
    Score: 0.006
  110. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. Retina. 2023 07 01; 43(7):1051-1063.
    View in: PubMed
    Score: 0.006
  111. Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023 06; 8(1).
    View in: PubMed
    Score: 0.006
  112. Risk Factors for the Development of Fellow Eye Horseshoe Retinal Tears Following Horseshoe Retinal Tear in the Presenting Eye. Ophthalmic Surg Lasers Imaging Retina. 2023 Jun; 54(6):338-345.
    View in: PubMed
    Score: 0.006
  113. USE OF OPTICAL COHERENCE TOMOGRAPHY IN DETECTING RETINAL TEARS IN ACUTE, SYMPTOMATIC POSTERIOR VITREOUS DETACHMENT. Retina. 2023 05 01; 43(5):802-807.
    View in: PubMed
    Score: 0.006
  114. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS? Registry. Ophthalmology. 2023 09; 130(9):937-946.
    View in: PubMed
    Score: 0.006
  115. Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: A meta-analysis of randomised trials. Acta Ophthalmol. 2024 Feb; 102(1):e31-e41.
    View in: PubMed
    Score: 0.006
  116. Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab. Ophthalmology. 2023 08; 130(8):795-803.
    View in: PubMed
    Score: 0.006
  117. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 12; 37(17):3551-3557.
    View in: PubMed
    Score: 0.006
  118. Noninferiority randomised trials in ophthalmology. Eye (Lond). 2023 10; 37(15):3059-3060.
    View in: PubMed
    Score: 0.006
  119. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul; 130(7):735-747.
    View in: PubMed
    Score: 0.006
  120. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM. Retina. 2023 03 01; 43(3):506-513.
    View in: PubMed
    Score: 0.006
  121. Interpreting results from randomized controlled trials: What measures to focus on in clinical practice. Eye (Lond). 2023 Oct; 37(15):3055-3058.
    View in: PubMed
    Score: 0.006
  122. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2023 06; 130(6):588-597.
    View in: PubMed
    Score: 0.006
  123. Re: Minimizing risks to patients by improving presentation of clinical trial results in geographic atrophy trials (Ophthalmol Retina. 2022;6:337-338). Ophthalmol Retina. 2022 11; 6(11):1109.
    View in: PubMed
    Score: 0.006
  124. Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study. Eye (Lond). 2023 Jun; 37(9):1928-1935.
    View in: PubMed
    Score: 0.006
  125. Optical Coherence Tomography Biomarkers for Conversion to Exudative Neovascular Age-related Macular Degeneration. Am J Ophthalmol. 2023 03; 247:137-144.
    View in: PubMed
    Score: 0.006
  126. OCT Risk Factors for Development of Atrophy in Eyes with Intermediate Age-Related Macular Degeneration. Ophthalmol Retina. 2023 03; 7(3):253-260.
    View in: PubMed
    Score: 0.006
  127. RETINAL VASCULAR BED AREA IN EYES WITH RETINAL VEIN OCCLUSION ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY: WAVE Study. Retina. 2022 10 01; 42(10):1883-1888.
    View in: PubMed
    Score: 0.006
  128. Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 10 01; 140(10):946-954.
    View in: PubMed
    Score: 0.006
  129. Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022 10 01; 140(10):936-945.
    View in: PubMed
    Score: 0.006
  130. Scleral Buckling Alone or in Combination with Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment Repair: A Meta-Analysis of 7,212 Eyes. Ophthalmologica. 2022; 245(4):296-314.
    View in: PubMed
    Score: 0.005
  131. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 09; 129(9):974-985.
    View in: PubMed
    Score: 0.005
  132. Refill-Exchange Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Trial Experience. Ophthalmic Surg Lasers Imaging Retina. 2022 05; 53(5):257-265.
    View in: PubMed
    Score: 0.005
  133. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Surv Ophthalmol. 2022 Sep-Oct; 67(5):1346-1363.
    View in: PubMed
    Score: 0.005
  134. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023 01; 37(1):6-16.
    View in: PubMed
    Score: 0.005
  135. Clinical impact of the worldwide shortage of verteporfin (Visudyne?) on ophthalmic care. Acta Ophthalmol. 2022 Nov; 100(7):e1522-e1532.
    View in: PubMed
    Score: 0.005
  136. Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study. Eye (Lond). 2023 03; 37(4):678-683.
    View in: PubMed
    Score: 0.005
  137. NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study. Retina. 2022 03 01; 42(3):426-433.
    View in: PubMed
    Score: 0.005
  138. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies. Retina. 2022 03 01; 42(3):511-518.
    View in: PubMed
    Score: 0.005
  139. Pars Plana Vitrectomy with and without Supplemental Scleral Buckle for the Repair of Rhegmatogenous Retinal Detachment: A Meta-analysis. Ophthalmol Retina. 2022 10; 6(10):871-885.
    View in: PubMed
    Score: 0.005
  140. Seeing the patient's perspective: a guide to patient-reported outcome measures and minimal important differences in ophthalmic research. Eye (Lond). 2022 07; 36(7):1339-1341.
    View in: PubMed
    Score: 0.005
  141. A clinician's guide to network meta-analysis. Eye (Lond). 2022 08; 36(8):1523-1526.
    View in: PubMed
    Score: 0.005
  142. The clinician's guide to interpreting a regression analysis. Eye (Lond). 2022 09; 36(9):1715-1717.
    View in: PubMed
    Score: 0.005
  143. Outcomes of Eyes Undergoing Multiple Surgical Interventions after Failure of Primary Rhegmatogenous Retinal Detachment Repair. Ophthalmol Retina. 2022 05; 6(5):339-346.
    View in: PubMed
    Score: 0.005
  144. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol. 2022 Jan 01; 140(1):20-28.
    View in: PubMed
    Score: 0.005
  145. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid. Ophthalmol Retina. 2022 05; 6(5):377-386.
    View in: PubMed
    Score: 0.005
  146. Pars plana vitrectomy versus scleral buckle: A comprehensive meta-analysis of 15,947 eyes. Surv Ophthalmol. 2022 Jul-Aug; 67(4):932-949.
    View in: PubMed
    Score: 0.005
  147. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis. Ophthalmology. 2022 05; 129(5):498-508.
    View in: PubMed
    Score: 0.005
  148. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta Ophthalmol. 2022 Sep; 100(6):e1199-e1208.
    View in: PubMed
    Score: 0.005
  149. The clinician's guide to p values, confidence intervals, and magnitude of effects. Eye (Lond). 2022 02; 36(2):341-342.
    View in: PubMed
    Score: 0.005
  150. Supplemental Scleral Buckle for the Management of Rhegmatogenous Retinal Detachment by Pars Plana Vitrectomy: A Meta-Analysis of Randomized Controlled Trials. Ophthalmologica. 2022; 245(2):101-110.
    View in: PubMed
    Score: 0.005
  151. Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data. Am J Ophthalmol. 2022 04; 236:12-19.
    View in: PubMed
    Score: 0.005
  152. Weakly-Supervised Vessel Detection in Ultra-Widefield Fundus Photography via Iterative Multi-Modal Registration and Learning. IEEE Trans Med Imaging. 2021 10; 40(10):2748-2758.
    View in: PubMed
    Score: 0.005
  153. Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. Br J Ophthalmol. 2023 03; 107(3):399-405.
    View in: PubMed
    Score: 0.005
  154. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 01; 139(9):946-955.
    View in: PubMed
    Score: 0.005
  155. Deep learning-enabled ultra-widefield retinal vessel segmentation with an automated quality-optimized angiographic phase selection tool. Eye (Lond). 2022 09; 36(9):1783-1788.
    View in: PubMed
    Score: 0.005
  156. RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2021 Aug 01; 41(8):1579-1586.
    View in: PubMed
    Score: 0.005
  157. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study. Ophthalmol Retina. 2022 03; 6(3):219-227.
    View in: PubMed
    Score: 0.005
  158. Exploring the angiographic-biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression. Br J Ophthalmol. 2022 10; 106(10):1444-1449.
    View in: PubMed
    Score: 0.005
  159. Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021 May 01; 139(5):542-547.
    View in: PubMed
    Score: 0.005
  160. Retinal vascular bed area on ultra-wide field fluorescein angiography indicates the severity of diabetic retinopathy. Br J Ophthalmol. 2022 08; 106(8):1126-1131.
    View in: PubMed
    Score: 0.005
  161. Frequency of Urgent or Emergent Vitreoretinal Surgical Procedures in the United States During the COVID-19 Pandemic. JAMA Ophthalmol. 2021 04 01; 139(4):456-463.
    View in: PubMed
    Score: 0.005
  162. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol. 2001 Mar; 158(3):1011-9.
    View in: PubMed
    Score: 0.005
  163. THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review. Retina. 2021 01 01; 41(1):1-19.
    View in: PubMed
    Score: 0.005
  164. The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found Symp. 2001; 240:212-25; discussion 225-31.
    View in: PubMed
    Score: 0.005
  165. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000 Dec 15; 60(24):7075-83.
    View in: PubMed
    Score: 0.005
  166. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021 07; 128(7):1027-1038.
    View in: PubMed
    Score: 0.005
  167. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY. Retina. 2020 Nov; 40(11):2175-2183.
    View in: PubMed
    Score: 0.005
  168. Effects of Long-Term DME Control With 0.2 ?g/Day Fluocinolone Acetonide Implant on Quality of Life: An Exploratory Analysis From the FAME Trial. Ophthalmic Surg Lasers Imaging Retina. 2020 11 01; 51(11):658-667.
    View in: PubMed
    Score: 0.005
  169. Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders. Transl Vis Sci Technol. 2020 10; 9(11):27.
    View in: PubMed
    Score: 0.005
  170. Automated vessel density detection in fluorescein angiography images correlates with vision in proliferative diabetic retinopathy. PLoS One. 2020; 15(9):e0238958.
    View in: PubMed
    Score: 0.005
  171. Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study. Am J Ophthalmol. 2021 02; 222:328-339.
    View in: PubMed
    Score: 0.005
  172. Ophthalmology conferences in the coronavirus disease 2019 era. Curr Opin Ophthalmol. 2020 Sep; 31(5):396-402.
    View in: PubMed
    Score: 0.005
  173. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2021 05; 5(5):409-419.
    View in: PubMed
    Score: 0.005
  174. Quantitative Comparison of Fundus Images by 2 Ultra-Widefield Fundus Cameras. Ophthalmol Retina. 2021 05; 5(5):450-457.
    View in: PubMed
    Score: 0.005
  175. Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study. Br J Ophthalmol. 2021 08; 105(8):1111-1115.
    View in: PubMed
    Score: 0.005
  176. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. Ophthalmol Retina. 2021 01; 5(1):60-70.
    View in: PubMed
    Score: 0.005
  177. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 08 01; 138(8):851-857.
    View in: PubMed
    Score: 0.005
  178. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 09; 20(9):999-1008.
    View in: PubMed
    Score: 0.005
  179. SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. Retina. 2020 Jun; 40(6):1029-1037.
    View in: PubMed
    Score: 0.005
  180. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2021 02; 105(2):253-257.
    View in: PubMed
    Score: 0.005
  181. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020 10; 127(10):1331-1344.
    View in: PubMed
    Score: 0.005
  182. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 04 01; 138(4):341-349.
    View in: PubMed
    Score: 0.005
  183. THE TEXAS TACO TECHNIQUE FOR INTERNAL LIMITING MEMBRANE FLAP IN LARGE FULL-THICKNESS MACULAR HOLES: A Short-Term Pilot Study. Retina. 2020 Mar; 40(3):552-556.
    View in: PubMed
    Score: 0.005
  184. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Ophthalmology. 2020 09; 127(9):1179-1188.
    View in: PubMed
    Score: 0.005
  185. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. Ophthalmology. 2020 06; 127(6):769-783.
    View in: PubMed
    Score: 0.005
  186. Intravitreal Combined Aflibercept?+ Anti-Platelet-Derived Growth Factor Receptor ? for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. Ophthalmology. 2020 02; 127(2):211-220.
    View in: PubMed
    Score: 0.005
  187. Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography. Am J Ophthalmol. 2020 01; 209:99-106.
    View in: PubMed
    Score: 0.005
  188. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. Eye (Lond). 2020 03; 34(3):480-490.
    View in: PubMed
    Score: 0.005
  189. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.
    View in: PubMed
    Score: 0.005
  190. Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1. Am J Ophthalmol. 2019 10; 206:154-160.
    View in: PubMed
    Score: 0.004
  191. Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration. Invest Ophthalmol Vis Sci. 2019 05 01; 60(6):2134-2139.
    View in: PubMed
    Score: 0.004
  192. Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. Am J Ophthalmol. 2019 10; 206:74-81.
    View in: PubMed
    Score: 0.004
  193. Real-World Trends in Intravitreal Injection Practices among American Retina Specialists. Ophthalmol Retina. 2019 08; 3(8):656-662.
    View in: PubMed
    Score: 0.004
  194. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 08; 126(8):1155-1170.
    View in: PubMed
    Score: 0.004
  195. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 06; 202:91-99.
    View in: PubMed
    Score: 0.004
  196. Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. JAMA Ophthalmol. 2019 01 01; 137(1):65-73.
    View in: PubMed
    Score: 0.004
  197. Predictors of Visual Acuity Outcomes Following Vitrectomy for Idiopathic Macular Hole. Ophthalmic Surg Lasers Imaging Retina. 2018 08 01; 49(8):566-570.
    View in: PubMed
    Score: 0.004
  198. Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2018 07 02; 59(8):3278-3285.
    View in: PubMed
    Score: 0.004
  199. When and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of Real-World Treatment Optimization Strategies. Ophthalmic Surg Lasers Imaging Retina. 2018 07 01; 49(7):S5-S15.
    View in: PubMed
    Score: 0.004
  200. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. Am J Ophthalmol. 2018 08; 192:84-90.
    View in: PubMed
    Score: 0.004
  201. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2018 08; 125(8):1304-1306.
    View in: PubMed
    Score: 0.004
  202. Five-Year Outcomes of Surgically Treated Symptomatic Epiretinal Membranes With and Without Internal Limiting Membrane Peeling. Ophthalmic Surg Lasers Imaging Retina. 2018 05 01; 49(5):296-302.
    View in: PubMed
    Score: 0.004
  203. Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study. Br J Ophthalmol. 2018 08; 102(8):1066-1071.
    View in: PubMed
    Score: 0.004
  204. Identification of factors to increase efficacy of telemedicine screening for diabetic retinopathy in endocrinology practices using the Intelligent Retinal Imaging System (IRIS) platform. Diabetes Res Clin Pract. 2018 Jun; 140:265-270.
    View in: PubMed
    Score: 0.004
  205. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology. 2018 07; 125(7):1054-1063.
    View in: PubMed
    Score: 0.004
  206. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefes Arch Clin Exp Ophthalmol. 2018 Mar; 256(3):511-518.
    View in: PubMed
    Score: 0.004
  207. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology. 2018 05; 125(5):683-690.
    View in: PubMed
    Score: 0.004
  208. Positive Visual Phenomena Following Implantation of the Argus II Retinal Prosthesis. Ophthalmic Surg Lasers Imaging Retina. 2017 12 01; 48(12):1022-1025.
    View in: PubMed
    Score: 0.004
  209. Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. Am J Ophthalmol. 2017 Aug; 180:110-116.
    View in: PubMed
    Score: 0.004
  210. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2017 02; 124(2):215-223.
    View in: PubMed
    Score: 0.004
  211. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. Ophthalmology. 2017 01; 124(1):74-81.
    View in: PubMed
    Score: 0.004
  212. Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad. Am J Ophthalmol. 2016 09; 169:xiv-xvi.
    View in: PubMed
    Score: 0.004
  213. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Can J Ophthalmol. 2015 Oct; 50(5):373-7.
    View in: PubMed
    Score: 0.003
  214. Not All Retina Is Created Equal: Metabolic Quantification of Ultra-Widefield Images. Ophthalmology. 2015 Dec; 122(12):2580-2.
    View in: PubMed
    Score: 0.003
  215. Exogenous fungal endophthalmitis: an analysis of isolates and susceptibilities to antifungal agents over a 20-year period (1990-2010). Am J Ophthalmol. 2015 Feb; 159(2):257-64.e1.
    View in: PubMed
    Score: 0.003
  216. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina. 2014 Sep; 34(9):1728-35.
    View in: PubMed
    Score: 0.003
  217. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology. 2014 Dec; 121(12):2432-42.
    View in: PubMed
    Score: 0.003
  218. Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. Ophthalmic Surg Lasers Imaging Retina. 2014 Jul-Aug; 45(4):312-7.
    View in: PubMed
    Score: 0.003
  219. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014 Sep; 121(9):1783-9.
    View in: PubMed
    Score: 0.003
  220. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Retina. 2014 Jan; 34(1):48-54.
    View in: PubMed
    Score: 0.003
  221. Lasers for the treatment of intraocular tumors. Lasers Med Sci. 2013 May; 28(3):1025-34.
    View in: PubMed
    Score: 0.003
  222. Pseudohypopyon as a clinical manifestation in metastatic lung carcinoma. Ophthalmic Surg Lasers Imaging. 2012 Feb 09; 43 Online:e1-4.
    View in: PubMed
    Score: 0.003
  223. Laser treatment for retinopathy of prematurity. Lasers Med Sci. 2013 Feb; 28(2):683-92.
    View in: PubMed
    Score: 0.003
  224. Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol. 2012 Jan; 153(1):162-6.e1.
    View in: PubMed
    Score: 0.003
  225. Comment on "fundus autofluorescence and multiple evanescent white dot syndrome". Retina. 2009 Oct; 29(9):1377-8; author reply 1378-9.
    View in: PubMed
    Score: 0.002
  226. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected]. J Biol Chem. 2004 Oct 08; 279(41):42719-25.
    View in: PubMed
    Score: 0.002
  227. The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours. J Pathol. 2004 Jul; 203(3):808-13.
    View in: PubMed
    Score: 0.002
  228. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol. 2003 Jun; 200(2):222-8.
    View in: PubMed
    Score: 0.001
  229. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer. 2003 Apr 07; 88(7):1065-70.
    View in: PubMed
    Score: 0.001
  230. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003 Feb 01; 21(3):473-82.
    View in: PubMed
    Score: 0.001
  231. Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Cancer Res. 2002 Dec; 8(12):3788-95.
    View in: PubMed
    Score: 0.001
  232. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002 Jun; 1(5):459-68.
    View in: PubMed
    Score: 0.001
  233. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer. 2002 Apr 22; 86(8):1276-82.
    View in: PubMed
    Score: 0.001
  234. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001 Nov 01; 61(21):7992-8.
    View in: PubMed
    Score: 0.001
  235. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res. 2001 Nov; 7(11):3399-403.
    View in: PubMed
    Score: 0.001
  236. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001 Aug 15; 19(16):3660-8.
    View in: PubMed
    Score: 0.001
  237. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001 Jul 01; 61(13):5262-7.
    View in: PubMed
    Score: 0.001
  238. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999 May 20; 399(6733):271-5.
    View in: PubMed
    Score: 0.001
  239. Regulation of gene expression by oxygen levels in mammalian cells. Adv Nephrol Necker Hosp. 1999; 29:191-206.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.